7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,890.60

+524.97

+0.68%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

Shanghai - Delayed Quote CNY

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (688796.SS)

77.35 -5.22 (-6.32%)

At close: October 30 at 3:00:01 PM GMT+8

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) Stock Price Faces Q3 Earnings Squeeze

Simply Wall St. 2d ago

2315.HK
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience

Business Wire 1mo ago

688796.SS
-6.32%
2315.HK
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience

Business Wire 1mo ago

688796.SS
-6.32%
2315.HK
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Business Wire 3mo ago

WHWK

688796.SS
-6.32%
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Business Wire 3mo ago

WHWK

688796.SS
-6.32%
Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour

Business Wire 4mo ago

688796.SS
-6.32%
02315
Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Business Wire 4mo ago

688796.SS
-6.32%

Mobilize your Website

View Site in Mobile | Classic

Share by: